RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs.

BASKING RIDGE, N.J., Aug.

NATICK, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2007, which runs from September 1 to 5 in Vienna, Austria.